Objective: The aim of this study is to investigate the association of preoperative platelet mass index (PMI) with tumor pathologic features and postoperative biochemical recurrence in patients undergoing radical prostatectomy due to localized prostate cancer. Materials and Methods: Data of 141 patients, who underwent radical prostatectomy for localized prostate cancer between April 2004 and April 2017, were retrospectively screened. Patient age, preoperative prostate-specific antigen (PSA) level, platelet count, mean platelet volume and PMI value, neutrophil-lymphocyte ratio (NLR), tumor grade, Gleason score, tumor volume, lymph node involvement, surgical margin positivity and biochemical recurrence at 3 months were all noted. The relationship of preoperative PMI value with age, PSA, pathologic parameters, surgical margin positivity and biochemical recurrence was evaluated. Results: The mean age of the patients was 61.79±5.98 years, the mean PSA value was 9.50±6.69 ng/mL, mean PMI was 2003.91±486.69, and the mean NLR was 2.79±2.06. There was no correlation of PMI value with PSA, pathological stage, Gleason score, lymph node involvement, tumor volume, surgical margin positivity, and biochemical recurrence. There was statistically significant negative correlation between PMI and Gleason score. Conclusion: In our study, we could not demonstrate preoperative PMI as a prognostic factor for early biochemical recurrence in patients undergoing radical prostatectomy for prostate cancer. To achieve a better conclusion that we can generalize, there is a need for prospective studies with larger patient series.
Amaç: Bu çalışmanın amacı, lokalize prostat kanseri nedeniyle radikal prostatektomi yapılan hastalarda preoperatif trombosit kitle indeksi (PMI) ile tümörün patolojik özellikleri ve postoperatif biyokimyasal nüks arasındaki ilişkiyi araştırmaktır. Gereç ve Yöntem: Nisan 2004 ile Nisan 2017 arasında lokalize prostat kanseri nedeniyle radikal prostatektomi yapılan 141 hastanın verileri retrospektif olarak tarandı. Hastaların yaş, preoperatif prostat spesifik antijen (PSA), trombosit sayısı, ortalama trombosit hacmi ve PMI değerleri, N/L oranı, tümör evresi, Gleason skoru, tümör hacmi, lenf nodu tutulumu, cerrahi sınır pozitifliği ve 3. ayda biyokimyasal nüks olup olmadığı kaydedildi. Ameliyat öncesi PMI değerinin yaş, PSA, patolojik parametreler, cerrahi sınır pozitifliği ve biyokimyasal nüks ile olan ilişkisi incelendi. Bulgular: Hastaların yaş ortalaması 61,79±5,98 yıl, ortalama PSA değeri 9,50±6,69 ng/mL, ortalama PMI değeri 2003,91±486,69 ve ortalama N/L oranı 2,79±2,06 idi. PMI değeri ile PSA, patolojik evre, Gleason skoru, lenf nodu tutulumu, tümör hacmi, cerrahi sınır pozitifliği, biyokimyasal nüks arasında bir korelasyon izlenmedi. PMI ile Gleason skoru arasında istatistiksel olarak anlamlı negatif korelasyon izlendi. Sonuç: Çalışmamızda prostat kanseri nedeniyle radikal prostatektomi uygulanmış hastalarda ameliyat öncesi PMI değerini, erken biyokimyasal nüks için prognostik bir faktör olarak gösteremedik. Genelleme yapabileceğimiz daha iyi bir sonuç elde etmek için, daha geniş hasta serileri ile prospektif olarak tasarlanmış çalışmalara ihtiyaç vardır.
Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell 2010;140:883-899.
Nording HM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis. Front Immunol 2015;6:98.
Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001;98:2720-2725.
Katoh N. Platelets as versatile regulators of cutaneous inflammation. J Dermatol Sci 2009;53:89-95.
Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-307.
Okur N, Buyuktiryaki M, Uras N, Oncel MY, Ertekin O, Canpolat FE, Oguz SS. Platelet mass index in very preterm infants: can it be used as a parameter for neonatal morbidities? J Matern Fetal Neonatal Med 2016;29:3218-3222.
Korkmaz L, Baştuğ O, Ozdemir A, Korkut S, Karaca C, Akin MA, Gunes T, Kurtoglu S, Ozturk MA. The efficacy of propranolol in retinopathy of prematurity and its correlation with the platelet mass index. Curr Eye Res 2017;42:88-97.
Huang XZ, Chen WJ, Zhang X, Wu CC, Zhang CY, Sun SS, Wu J. An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis. Dis Markers 2017;2017:1053125.
Wang W, Bian C, Xia D, He JX, Hai P, Zhao R, Wang YY. Combining Carcinoembryonic Antigen and Platelet to Lymphocyte Ratio to Predict Brain Metastasis of Resected Lung Adenocarcinoma Patients. Biomed Res Int 2017;2017:8076384.
Song W, Tian C, Wang K, Zhang RJ, Zou SB. Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis. PloS One 2017;12:e0178762.
Shirai Y, Shiba H, Sakamoto T, Horiuchi T, Haruki K, Fujiwara Y, Futagawa Y, Ohashi T, Yanaga K. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery 2015;158:360-365.
Yang HJ, Jiang JH, Liu QA, Zhou CM, Du YF, Wu T, Chen NZ, Xiang BD. Preoperative plateletto-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection. Tumour Biol 2017;39:1010428317707375.
Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, Jamaris S, Taib NA. Utility of pretreatment neutrophil-lymphocyte ratio and plateletlymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 2015;113:150-158.
Fuentes HE, Oramas DM, Paz LH, Wang Y, Andrade XA, Tafur AJ. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer. J Gastrointest Cancer 2017.
Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Lee JH. Clinical significance of preoperative neutrophil-lymphocyte versus plateletlymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216-222.
Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466-472.
Baranyai Z, Krzystanek M, Jósa V, Dede K, Agoston E, Szász AM, Sinkó D, Szarvas V, Salamon F, Eklund AC, Szállási Z, Jakab F. The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer. Thromb Haemost 2014;111:483-490.
Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2014;27:32- 41.
McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223-226.
Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 2004;29:132-140.
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178-185.
Zhang GM, Zhu Y, Ma XC, Qin XJ, Wan FN, Dai B, Sun LJ, Ye DW. Pretreatment Neutrophil-toLymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy. Medicine (Baltimore) 2015;94:e1473.
Kwon YS, Han CS, Yu JW, Kim S, Modi P, Davis R, Park JH, Lee P, Ha YS, Kim WJ, Kim IY. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clin Genitourin Cancer 2016;14:1-8.
Zisk JL, Mackley A, Clearly G, Chang E, Christensen RD, Paul DA. Transfusing neonates based on platelet count vs. platelet mass: a randomized feasibilitypilot study. Platelets 2014;25:513-516.
Kahvecioglu D, Erdeve O, Alan S, Cakir U, Yildiz D, Atasay B, Arsan S. The impact of evaluating platelet transfusion need by platelet mass index on reducing the unnecessary transfusions in newborns. J Matern Fetal Neonatal Med 2014;27:1787-1789.
Gerday E, Baer VL, Lambert DK, Paul DA, Sola-Visner MC, Pysher TJ, Christensen RD. Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit. Transfusion 2009;49:2034- 2039.
Christensen RD. Platelet transfusion in the neonatal intensive care unit: benefits, risks, alternatives. Neonatology 2011;100:311-318.
Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001;22:1561-1571.
Zhang F, Chen Z, Wang P, Hu X, Gao Y, He J. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumour Biol 2016;37:9323-9331.
Gu M, Zhai Z, Huang L, Zheng W, Zhou Y, Zhu R, Shen F, Yuan C. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis with invasive breast cancer. Breast Cancer 2016;23:752-760.
Cho SY, Yang JJ, You E, Kim BH, Shim J, Lee HJ, Lee WI, Suh JT, Park TS. Mean platelet volume/ platelet count ratio in hepatocellular carcinoma. Platelets 2013;24:375-377.
Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/ platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer 2014;83:97-101.
Kumagai S, Tokuno J, Ueda Y, Marumo S, Shoji T, Nishimura T, Fukui M, Huang CL. Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Mol Clin Oncol 2015;3:197-201.
Mezouar S, Frere C, Darbousset R, Mege D, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C. Role of platelets in cancer and cancerassociated thrombosis: experimental and clinical evidences. Thromb Res 2016;139:65-76.
Meikle CK, Kelly CA, Garg P, Wuescher LM, Ali RA, Worth RG. Cancer and thrombosis: the platelet perspective. Front Cell Dev Biol 2016;4:147.
Ha YS, Chung JW, Chun SY, Choi SH, Lee JN, Kim BS, Kim HT, Kim TH, Byun SS, Hwang EC, Kang SH, Hong SH, Chung J, Kwak C, Kim YJ, Kwon TG; KORCC study group. Impact of preoperative thrombocytosis on prognosis after surgical treatment in pathological T1 and T2 renal cell carcinoma: results of a multi-institutional comprehensive study. Oncotarget 2017;8:64449- 64458.
Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295- 1300.
Takeuchi H, Fukuyama S, Kubo N, Hiroshige S, Kawanaka H, Yoshikawa Y, Yano T. The prognostic significance of the preoperative platelet-lymphocyte ratio in Japanese patients with localized breast cancer. Adv Breast Cancer Res 2016;5:49-57.
Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS One 2017;12:e0177137.